The bill amends Minnesota Statutes 2024, section 151.741, subdivision 2, to modify the provisions regarding the annual registration fee for insulin manufacturers. The annual fee is set at $100,000, with notifications to manufacturers starting on November 1, 2024, and each subsequent November 1. A significant addition to the law is the requirement for the commissioner of health to provide technical assistance to the board using available data sources, including data collected under section 62U.04.

Additionally, the bill outlines the conditions under which a manufacturer may request an exemption from the registration fee. The criteria for exemption have been updated to focus on the total wholesale acquisition cost of dispensing claims for prescription insulin products within or into Minnesota, rather than the previous requirement related to gross revenue from sales. This change aims to streamline the exemption process and ensure that it is based on relevant financial metrics related to insulin distribution in the state.

Statutes affected:
Introduction: 151.741